Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

Canadian Journal of Psychiatry

Volumn 63, Issue 11, 2018, Pages 730-739

  Martino, Davide ^a,b   Karnik, Vikram ^a   Osland, Sydney ^a   Barnes, Thomas R E ^c   Pringsheim, Tamara M ^a,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

extrapyramidal syndromes; schizophrenia; systematic reviews; tardive dyskinesia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

AKATHISIA; COCHRANE LIBRARY; DRUG DOSE; DYSTONIA; HUMAN; META ANALYSIS; MOTOR DYSFUNCTION; PARKINSONISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT DURATION; TREMOR;

EID: 85047417424     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743718777392     Document Type: Review

References (57)

1. Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin. 2015;33:153–174
2. Solmi M, Murru A, Pacchiarotti I. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777
3. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40:1113–1117
4. Lima AR, Bacalcthuk J, Barnes TR. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia (meta-analysis review). Cochrane Database Syst Rev. 2004;(4):CD001946. doi: 10.1002/14651858.CD001946.pub2
5. Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord. 1997;12:302–305
6. Tinazzi M, Ottaviani S, Isaias IU. [123I]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord. 2008;23:1825–1829
7. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78:1136–1147
8. Adrianzén C, Arango-Dávila C, Araujo DM. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol. 2010;25:439–447
9. Gervin M, Barnes TRE. Assessment of drug-related movement disorders in schizophrenia. Advances in Psychiatric Treatment. 2000;6:332–341
10. Bebbington PE, Angermeyer M, Azorin JM, Marwaha S, Marteau F, Toumi M. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl. 2009;(438):22–28
11. Leucht S, Cipriani A, Spineli L. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013;382:951–962
12. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–598
13. Martino D, Morgante F. Movement disorders and chronic psychosis: Five new things. Neurol Clin Pract. 2017;7:163–169
14. Pope A, Adams C, Paton C, Weaver T, Barnes TRE. Assessment of adverse effects in clinical studies of antipsychotic medication: Survey of methods used. Br J Psychiatry. 2010:197:67–72
15. Silveira da Mota Neto JI, Soares BGO, Silva de Lima M. Amisulpride for schizophrenia. Cochrane Database Syst Rev. 2002;(2):CD001357. doi: 10.1002/14651858.CD001357
16. Komossa K, Rummel-Kluge C, Hunger H. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; (1):CD006624. doi:10.1002/14651858.CD006624.pub2
17. Khanna P, Suo T, Komossa K. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Rev. 2014;(1):CD006569. doi:10.1002/14651858.CD006569.pub5
18. Belgamwar RB, El-Sayeh HGG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011;(8):CD006622. doi:10.1002/14651858.CD006622.pub2
19. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008;(3):CD006617. doi:10.1002/14651858.CD006617.pub3
20. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD004578. doi: 10.1002/14651858.CD004578.pub3
21. Hay A, Byers A, Sereno M, Basra MK, Dutta S. Asenapine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015;(11):CD011458. doi:10.1002/14651858.CD011458.pub2
22. Mazhari S, Esmailian S, Shah-Esmaeili A, Goughari AS, Bazrafshan A, Zare M. Chlorpromazine versus clotiapine for schizophrenia. Cochrane Database Syst Rev. 2017;(4):CD011810. doi:10.1002/14651858.CD011810.pub2
23. Zare M, Bazrafshan A. Chlorpromazine versus metiapine for schizophrenia. Cochrane Database Syst Rev. 2017;(3):CD011655. doi:10.1002/14651858.CD011655.pub2
24. Saha KB, Bo L, Zhao S, Xia J, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2016;(4):CD010631. doi:10.1002/14651858.CD010631.pub2
25. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlopromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014;(1):CD000284. doi:10.1002/14651858.CD000284.pub2
26. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;(1):CD000059. doi:10.1002/14651858.CD000059.pub2
27. Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017; (3):CD006324. doi:10.1002/14651858.CD006324.pub3
28. Asenjo Lobos C, Komossa K, Rummel-Kluge C. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(11):CD006633. doi:10.1002/14651858.CD006633.pub2
29. Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev. 2015;(1):CD009831. doi:10.1002/14651858.CD009831.pub2
30. Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2014;(7):CD009268. doi:10.1002/14651858.CD009268.pub2
31. Adam CE, Bergma H, Irvin CB, Lawri S. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2013;(11):CD003082. doi:10.1002/14651858.CD003082.pub2
32. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst Rev. 2008;(1):CD004278. doi:10.1002/14651858.CD004278.pub2
33. Komossa K, Rummel-Kluge C, Hunger H. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654. doi:10.1002/14651858.CD006654.pub2
34. Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD005237. doi:10.1002/14651858.CD005237.pub2
35. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005;(2):CD001359. doi:10.1002/14651858.CD001359.pub2
36. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012;(6):CD008296. doi:10.1002/14651858.CD008296.pub2
37. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;(11):CD006625. doi:10.1002/14651858.CD006625.pub3
38. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013;(5):CD007815. doi:10.1002/14651858.CD007815.pub2
39. Srisurapanont M, Maneeton B, Maneeton N, Lankappa S, Gandhi R. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD000967. doi:10.1002/14651858.CD000967.pub2
40. Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016;(12):CD006918. doi:10.1002/14651858.CD006918.pub3
41. Sampson S, Hosalli P, Furtado VA, Davis JM. Risperidone (depot) for schizophrenia. Cochrane Database Syst Rev. 2016;(4):CD004161. doi:10.1002/14651858.CD004161.pub2
42. Komossa K, Rummel-Kluge C, Schwarz S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;(1):CD006626. doi:10.1002/14651858.CD006626.pub2
43. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009;(4):CD007474. doi:10.1002/14651858.CD007474.pub2
44. Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD005237. doi:10.1002/14651858.CD005237.pub2
45. Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003; (2):CD000440. doi: 10.1002/14651858.CD000440
46. Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014;(4):CD007811. doi:10.1002/14651858.CD007811.pub2
47. Wang J, Omori IM, Fenton M, Soares BGO. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD008125. doi:10.1002/14651858.CD008125.pub2
48. Soares BGO, Fenton M, Chue P. Sulpiride for schizophrenia. Cochrane Database Syst Rev. 1999;(1):CD001162. doi:10.1002/14651858.CD001162
49. Komossa K, Rummel-Kluge C, Hunger H. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;(4):CD006627. doi:10.1002/14651858.CD006627.pub2
50. Bagnall AM, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000;(4):CD001945. doi:10.1002/14651858.CD001945
51. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988;244:685–693
52. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3:353–359
53. 2 receptors. Nat Commun. 2017;8:763
54. 2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1998;251:238–246
55. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001;158:360–369
56. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001;297:711–717
57. Zhu Y, Krause M, Huhn M. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4:694–705